A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Popular drugs like Ozemic and Monjauro aid in managing diabetes by lowering blood sugar levels. They have surged in ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

No difference in thyroid cancer risk was found for adults with type 2 diabetes using a GLP-1 receptor agonist vs. those using a DPP-IV inhibitor. Women may have a lower risk for thyroid cancer ...

GLP-1 inhibitors such as semaglutide and tirzepatide have become popular and effective for weight loss and blood sugar control. However, they’re not without side effects. Keep in mind the following to ...

More thyroid cancers were detected soon after starting a GLP-1 receptor agonist than other diabetes drugs, a secondary ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...